Business development executives on site at this year’s BIO International Convention in San Diego noted that while the total dollar value of deals announced so far in 2024 may not be as high as it was at mid-year in 2023, negotiations for new partnerships and M&A are keeping dealmakers busy.
Competitive Dealmaking Market Shifts To Smaller M&A, Partnering
Acquisition Numbers Rise, Values Fall In Q1
Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.
More from BIO
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.